REDWOOD CITY, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- biotricity, Inc. (OTCQB:BTCY), a healthcare technology company dedicated to delivering innovative, medically relevant biometric remote monitoring solutions, has appointed Dr. Rony Shimony to its Board of Advisors (BOA). Shimony is an internationally recognized clinical cardiologist who brings to the company over twenty-five years of experience in cardiac patient care and related technology.
“I am very pleased to join biotricity’s board of advisors and share my experiences and insights to help the company address major cardiovascular diseases and improve patient’s outcomes. Cardiovascular diseases claim more than 17 million lives worldwide, more than any other disease and more than all cancers combined. CDC data reports that heart disease claims 600,000 Americans on a yearly basis. Heart disease affects 1 out of 4 males and 1 out of 3 females and there are 750,000 strokes a year in the US, of which 175,000 reoccur,” commented Shimony. “The size of the population affected is staggering. biotricity’s next-generation monitor detects life threatening arrhythmias and arrhythmias that might lead to stroke, such as atrial fibrillation, in real-time. Falls due to bradycardia events and other arrhythmias can lead to disability and death, especially in the elderly, making response and patient location critical. With built in location capability, biotricity’s monitor can potentially reduce response times and improve outcomes.”
Dr. Shimony, MD, FACC and Associate Professor of Medicine and Cardiology at the Icahn School of Medicine at Mount Sinai in New York, brings vast knowledge and expertise in Cardiovascular Disease to biotricity, and will help advise the company as it rolls out its upcoming innovative biometric device. Dr. Shimony joins the existing members of the Board of Advisors—Dr. David Liepert, Thomas Nelson, Bernard Rice, John Rother and Danny Sands—and will assist in guiding the company on its growth and product development to positively affect patient outcomes.
Dr. Shimony is the director of Clinical Cardiology at Mount Sinai West (MSW). MSW is part of the internationally renowned Mount Sinai Health System, which encompasses a full range of cardiovascular services, including cardiovascular prevention, complex cardiac interventions, full electrophysiology services, device implantation and complex ablations, heart failure and heart transplant program with a comprehensive cardiothoracic surgical program. Shimony and his team specialize in the treatment of complex cardiovascular cases, integrating all aspects of cardiovascular medicine, coronary CT Angiography, cardiac risk reduction, electrophysiology and device (ICD/Pacemaker) management, with approximately 1,000 device visits per year.
Dr. Shimony received his BS degree in Biology, graduating Summa Cum Laude and Phi Beta Kappa from The University of New York at Albany and received his MD from The University of New York at Buffalo School of Medicine and Biomedical Sciences in 1984. He previously served as the Director of Lenox Hill Heart and Vascular out-patient Center in Manhattan, as well as the Director of Mount Sinai Heart and Vascular Center Midtown.
“We look forward to leveraging Dr. Shimony’s clinical and diagnostic expertise to help drive the adoption of our next-generation medical-grade wearables in mainstream healthcare practices,” said Waqaas Al-Siddiq, co-founder, president and CEO of biotricity. “As heart disease remains the #1 killer globally, representing 31 percent of all deaths worldwide, we are thrilled to have Dr. Shimony bring his expertise to our advisory board where he will collaborate with other talented and accomplished members to help drive our strategic vision of evolving the healthcare industry.”
Dr. Shimony has received numerous awards, including a special Congressional Recognition for Outstanding and Valuable Service to the Community. He has been listed in America’s Top Doctors each year from 1999-2016, and was listed in New York Magazine's Best Doctors issue in June 2012. He is an active member of the Heart Rhythm Society, the European Society of Cardiology and the European Heart Rhythm Association, and is a Fellow of the American College of Cardiology.
About Biotricity, Inc.
biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Media Contacts McCoin & Smith Communications Inc. Chris McCoin, Chris@mccoinsmith.com, 508-429-5988 Richard Smith, firstname.lastname@example.org, 978-433-3304 Investor Relations: Michael Koehler Liolios Group, Inc. BTCY@liolios.com 949-574-3860